Reliable and Objective Antibody Analysis with the New Agilent ProteoAnalyzer System
September 20th 2024This technical overview compares the characterization of NISTmAb using the ProteoAnalyzer with published NIST data obtained via traditional single capillary CE-SDS technology. The results show strong correlation with the reference data, confirming that the ProteoAnalyzer is a reliable tool for analytical workflows.
Risk-based approach to selecting environmental monitoring locations SmartNotes
August 8th 2024Dr. Tim Sandle's SmartNote series discusses how a risk-based approach to environmental monitoring helps facilities maintain control over their environment and supports quality assurance efforts. Plus, they highlight the importance of selecting appropriate monitoring locations and taking proactive measures based on monitoring results to ensure consistent environmental quality and mitigate potential risks to product safety and integrity.
Enhanced mRNA Production by in Vitro Transcription and Co-transcriptional Capping
August 5th 2024Increasing mRNA yields using CleanCap® M6 pulse-feed protocol. This technical note reviews the in vitro transcription (IVT) kinetics of CleanCap M6, including those associated with a supplementary pulse-feed protocol to increase IVT yields and help lower the costs associated with mRNA manufacturing.
Mass Information on Charge Variants in Minutes, Not Weeks
August 2nd 2024Explore how an integrated, single platform imaged capillary isoelectric focusing (icIEF)-UV/MS workflow with the Intabio ZT system aims to tackle the challenge of charge heterogeneity profiling with a disruptive strategy that allows for separation, quantitation, and identification of individual charge variants to be achieved in minutes on a single platform.
Scalable Solutions for Novel Oral Solid Dose Development and Manufacturing
August 1st 2024Developing successful oral solid dosage forms necessitates partnering with a CDMO equipped with distinctive technologies and expertise to enable support across solid-state characterization, formulation development and scale-up manufacturing processes.
Optimizing Oligonucleotide Analysis
August 1st 2024Due to their ability to tackle targets that were considered undruggable, oligonucleotides represent a key cornerstone of the future of personalized medicine. This infographic presents the different types of therapeutic oligonucleotides and highlights some innovative solutions for their analysis.
Multi-Column Chromatography for mAb Capture and Viral Clearance
July 9th 2024Traditionally, producing biotherapeutics such as monoclonal antibodies required a multi-step process to remove impurities, including host-cell proteins, DNA, adventitious viruses, and antibody aggregates. However, by converting the process from batch chromatography to multi-column chromatography (MCC), there is potential to reduce costs and shorten production times for the capture and purification of high-quality mAbs.
Gibcoᵀᴹ CHO Cell Culture Solutions for Biomanufacturing
July 1st 2024Gain access to essential strategies and solutions for optimizing your CHO cell culture workflow. This exclusive resource offers valuable insights and practical guidance tailored to the challenges of scaling up monoclonal antibody manufacturing with CHO cells.
Navigate your Efficient-Pro journey with professional support
July 1st 2024This asset outlines the comprehensive support and guidance offered by the FAS team for optimizing monoclonal antibody (mAb) manufacturing processes using the Efficient-Pro medium and feeds. Readers will learn about the tailored assistance provided at every stage, including troubleshooting, recommendations, ongoing support, site visits, and prioritization of confidentiality.
Accelerate your mAb manufacturing workflow
July 1st 2024In this asset, you will discover how the Gibco Efficient-Pro system can revolutionize your mAb manufacturing workflow. It provides insights into optimizing CHO cell productivity, enhancing product titers and protein quality, streamlining process efficiency, and leveraging a reliable supply network.
Should CO2 be a Critical Process Parameter?
June 28th 2024Download the white paper and learn how Implementing Real-Time Control of Carbon Dioxide can Impact Productivity at R&D and Production Scale Bioreactors. Dissolved CO₂ is a Critical Process Parameter (CPP) in biopharma production processes, as it has a direct impact on product titer and its critical quality attributes. It influences other culture parameters like extracellular and intracellular pH, as well as key performance indicators such as Viable Cell Density. Uncontrolled dissolved carbon dioxide levels in the bioreactor can result in growth inhibition, lower product titer, and decreased product quality.
Biopharma Downstream Critical Process Parameters
June 28th 2024Download our comprehensive white paper and gain valuable insights into the critical process parameters and advance sensor technologies that can revolutionize your Biopharma Downstream Process (DSP). Discover strategies and techniques to optimize efficiency, improve product quality, and ensure the safety and efficacy of your biopharmaceutical products.
All Things mRNA: Strategies for Effective mRNA Vaccine and Therapeutic Development
June 24th 2024mRNA vaccines and therapeutics continue to reshape medicine, providing unique opportunities to prevent and treat a wide range of diseases. In order to unleash the full potential of mRNA, however, one must consider various factors.
High Throughput Phage Display for Accelerated Antibody Drug Discovery
June 24th 2024Bio-Rad Laboratories, Inc., Pioneer™ Antibody Discovery Platform helps streamline the phage display-based discovery process and provides researchers with superior identification of high-quality therapeutic antibodies.